Table 1.
Patient demographics, surgical and oncological data.
| Pt. nr. | Age (years) | Primary tumor | Primary tumor site | Primary tumor to PM (months) | Primary tumor surgery | Previous chemotherapy lines and radiotherapy | Combined systemic chemotherapy | Drugs | First PIPAC ECOG PS | Survival from first PIPAC (months) | Survival from PM (months) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 73 | CC | Gallbladder | 2.1 | Cholecystectomy | GEMOX | None | Oxa | 1 | 19.3 | 28.9 |
| 2 | 80 | CC | Gallbladder | 42.3 | Cholecystectomy + hepatic resection | GEM | None | Oxa | 2 | 10.9 | 12.3 |
| 3 | 73 | PDAC | Head | 2.8 | – | GEM –> FOLFIRINOX –>PACLITAXEL | TAXOL | Cis + Dox | 1 | 16.3 | 27.0 |
| 4 | 52 | PDAC | Head | 34.7 | Whipple Operation | FOLFIRINOX–> GEM –> FOLFOX | FOLFIRI | Cis + Dox | 2 | 10.0 | 18.2 |
| 5 | 78 | PDAC | Body–tail | Synchronous | None | GEM + NAB-PACLITAXEL | GEM + NAB-PACLITAXEL | Oxa | 1 | 7.8 | 11.0 |
| 6 | 55 | PDAC | Head | Synchronous | None | FOLFIRINOX | FOLFIRI | Cis + Dox | 0 | 10.0 | 21.6 |
| 7 | 43 | PDAC | Body–tail | Synchronous | None | GEM + NAB-PACLITAXEL | FOLFOX | Oxa | 1 | 5.8 | 22.0 |
| 8 | 61 | PDAC | Head | 16.8 | Whipple Operation | GEM –> RT | FOLFIRI | Oxa | 2 | 9.3 | 10.6 |
| 9 | 64 | PDAC | Body–tail | 18.0 | Pancreatic tail resection | GEM | FOLFIRI | Oxa | 1 | 6.9 | 7.5 |
| 10 | 87 | PDAC | Head | 12.9 | None | Capecitabine | Capecitabine | Oxa | 1 | 14.9 | 16.2 |
| 11 | 55 | PDAC | Body–tail | Synchronous | None | FOLFOX | None | Oxa | 1 | 1.7 | 9.0 |
| 12 | 70 | PDAC | Body–tail | Synchronous | None | GEM + NAB-PACLITAXEL | FOLFOX | Oxa | 1 | 9.7 | 17.9 |
| 13 | 60 | PDAC | Head | 11.2 | Whipple Operation | GEM –> FOLFOX | None | Oxa | 2 | 16.0 | 40.9 |
| 14 | 66 | PDAC | Body–tail | 8.2 | Pancreatic tail resection | GEM –> RT | None | Cis + Dox | 2 | 3.4^ | 13.0^ |
| 15 | 58 | PDAC | Head | 14.3 | Whipple Operation | FOLFIRI + GEM –> RT | GEM + NAB-PACLITAXEL | Cis + Dox | 0 | 9.9 | 16.1 |
| 16 | 64 | CC | Gallbladder | 10.4 | Cholecystectomy | GEM + Cis | None | Cis + Dox | 0 | 8.2* | 9.0* |
| 17 | 63 | PDAC | Head | Synchronous | None | GEM | GEM | Oxa | 2 | 1.7 | 7.0 |
| 18 | 42 | CC | Biliary tract | 6.0 | Hepatic resection | GEM | None | Cis + Dox | 0 | 6.8* | 15.3* |
| 19 | 64 | CC | Biliary tract | 6.0 | Hepatic resection | GEM + Cis | None | Oxa | 2 | 6.8* | 11.7* |
| 20 | 69 | CC | Gallbladder | 29.0 | Cholecystectomy | GEM + Cis | None | Cis + Dox | 1 | 1.4 | 11.9 |
^
Lost at follow-up.
*
Alive.
CC, cholangiocarcinoma; Cis, cisplatin; Dox, doxorubicin; ECOG PS, Eastern Cooperative Oncology Group performance status; GEM, gemcitabine; GEMOX, gemcitabine + oxaliplatin; Oxa, oxaliplatin; FOLFIRINOX, folinic acid, flurouracil, irinotecan, oxaliplatin; FOLFOX, folinic acid, flurouracil, oxaliplatin; FOLFIRI, folinic acid, flurouracil, irinotecan; PDAC, pancreatic adenocarcinoma; PIPAC, pressurized intraperitoneal aerosol chemotherapy; PM, peritoneal metastases; Pt. nr., patient number; RT, radiotherapy.